Alseroxylon

Alseroxylon
	Reserpine, the major component of alseroxylon
Clinical data
ATC code	C02AA03 (WHO) ;
Identifiers
CAS Number	8001-95-4 ; active moiety: 8063-17-0 ;
DrugBank	DB00386 ;
ChemSpider	None;
UNII	H192N84N1G; active moiety: H192N84N1G ;
ChEMBL	ChEMBL1201454 ;
Chemical and physical data
Formula	Varies
	(what is this?) (verify)

Alseroxylon (Rautensin, Rauwiloid) is a norepinephrine reuptake inhibitor that has been investigated in the treatment of hypertension^[1] and angina pectoris and as a sedative in psychosis.^[2] It was at one time approved for use in the United States, but has since been discontinued.^[3]

Alseroxylon is a purified fat-soluble extract of the root of Rauvolfia serpentina, containing reserpine and other nonadrenolytic amorphous alkaloids.^[2]

References

^ Green RS, Davolos D (May 1956). "A long-term study of the effect of crude Rauwolfia serpentina and of its alseroxylon fraction in patients with hypertension". The American Journal of Medicine. 20 (5): 760–73. doi:10.1016/0002-9343(56)90158-9. PMID 13313574.
^ ^a ^b DrugBank DB00386
^ Approved Drug Products with Therapeutic Equivalence Evaluations (33rd ed.). 2013. {{cite book}}: |work= ignored (help)

[1] Green RS, Davolos D (May 1956). "A long-term study of the effect of crude Rauwolfia serpentina and of its alseroxylon fraction in patients with hypertension". The American Journal of Medicine. 20 (5): 760–73. doi:10.1016/0002-9343(56)90158-9. PMID 13313574.

[DrugBank-2] DrugBank DB00386

[3] Approved Drug Products with Therapeutic Equivalence Evaluations (33rd ed.). 2013. {{cite book}}: |work= ignored (help)

[1]

[2]

[3]